Vitiligo in patients with metastatic melanoma: A good prognostic sign

Nordlund, James J.; Kirkwood, John M.; Forget, Bernadette M.; Milton, G. W.; Albert, Daniel M.; Lerner, Aaron B.

doi:10.1016/s0190-9622(83)70182-9

Cited by 276 publications

(187 citation statements)

References 19 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Clinical observations have suggested, albeit indirectly, that an immune response directed against differentiation antigens expressed by normal pigment cells might influence the course of metastatic melanoma (4,5). In this regard, melanosomal antigens potentially could be recognized by the immune system .…”

mentioning

confidence: 99%

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.

Setaluri

Bouchard

Houghton

1990

The Journal of Experimental Medicine

186

123

View full text Add to dashboard Cite

The gp75 antigen is an abundant intracellular glycoprotein expressed in melanosomes of human pigmented melanocytes and melanomas. IgG antibodies in sera of a patient with metastatic melanoma have been shown to immunoprecipitate gp75, suggesting that immunological tolerance against gp75 can be broken. The mouse mAb TA99, which specifically recognizes gp75, was used to isolate and purify the antigen. Amino acid sequences of three internal peptides were determined from the purified gp75 polypeptide. cDNA clones were isolated by screening with oligonucleotides based on these peptide sequences. The gp75 peptides and cDNA had approximately 90% identity with, respectively, the derived amino acid and nucleotide sequences of a mouse gene that maps to the b (brown) locus. The brown locus determines coat color in the mouse, suggesting that gp75 regulates or influences the type of melanin synthesized.

show abstract

mentioning

confidence: 99%

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.

Setaluri

Bouchard

Houghton

1990

The Journal of Experimental Medicine

186

123

View full text Add to dashboard Cite

show abstract

“…In the 63 patients who were disease-free, median survival of those with total lymphocytes <2000/mm 3 was 965 days, while the median was not reached in those with >2000/mm 3 , without significant differences (log rank= .00, df= 1, p= .9486). Within the 23 patients with disseminated disease, no statistically significant differences in median survival were found either between patients with lymphocyte counts > or < 2000/mm 3 (197 days for patients with <2000 versus 202 days for those with >2000/mm 3 (log rank= .00, df = 1, p= .9486).…”

Section: Resultsmentioning

confidence: 87%

“…Total lymphocyte counts are significantly higher in patients who are disease-free. In addition, patients with total lymphocyte counts above 2000 cells/mm 3 have significantly longer survival. As for lymphocyte subpopulations both B lymphocyte (CD19) and NK lymphocyte (CD56) counts are also significantly higher in patients who are disease-free.…”

Section: Discusionmentioning

confidence: 99%

“…They concluded that the acquired immunodeficiency present in patients with esophageal cancer is due to severe malnutrition and not to the neoplasm itself 2 . The importance of the immune system in metastatic melanoma, as evidenced by lymphoid infiltration into tumour and surrounding tissues and reported spontaneous remissions, has been known for long [3][4][5][6][7][8] . A number of studies aimed to identifying molecular alterations in the antitumor immune response in patients with melanoma have been performed in the last years 9,10 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of quantitative immune alterations in melanoma patients

Andrés¹,

Mayordomo²,

Isla³

et al. 2006

Oncología (Barc.)

View full text Add to dashboard Cite

Summary• Purpose: The immune response is altered in patients with neoplasms. Immunosuppression has important consequences in patients with melanoma. The aim of this study was to assess quantitative immune alterations in melanoma patients..• Material and methods: We obtained a peripheral blood sample in EDTA from 86 melanoma patients (63 of them disease-free and 23 with distant disease). Total leukocytes and lymphocytes, B lymphocytes (CD19), types CD3, CD4, CD8 lymphocytes, and NK lymphocytes (CD56) were counted by determining the surface markers by flow cytometry, using a Coulter Epics Elite (Coulter Corp.). IgA, IgG, IgE and IgM were assayed by nephelometric methods employing a Hyland PDQ laser nephelometer.

show abstract

“…Early clinical observations indicated that the presence of vitiligo has a favorable influence on the average fiveyear survival rate of patients with malignant melanoma (Bystryn et al, 1987;Nordlund et al, 1983). Furthermore, Il-2 based immunotherapy studies in melanoma patients suggested a role for autoreactive CTL in vitiligo (Rosenberg, 1997).…”

Section: Cellular Immune Responsementioning

confidence: 99%